180 related articles for article (PubMed ID: 25796344)
1. Vascular smooth muscle cells contribute to APOL1-induced podocyte injury in HIV milieu.
Lan X; Wen H; Saleem MA; Mikulak J; Malhotra A; Skorecki K; Singhal PC
Exp Mol Pathol; 2015 Jun; 98(3):491-501. PubMed ID: 25796344
[TBL] [Abstract][Full Text] [Related]
2. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
[TBL] [Abstract][Full Text] [Related]
3. Impact of APOL1 polymorphism and IL-1β priming in the entry and persistence of HIV-1 in human podocytes.
Mikulak J; Oriolo F; Portale F; Tentorio P; Lan X; Saleem MA; Skorecki K; Singhal PC; Mavilio D
Retrovirology; 2016 Sep; 13(1):63. PubMed ID: 27599995
[TBL] [Abstract][Full Text] [Related]
4. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.
Khatua AK; Cheatham AM; Kruzel ED; Singhal PC; Skorecki K; Popik W
Am J Physiol Cell Physiol; 2015 Jul; 309(1):C22-37. PubMed ID: 25924622
[TBL] [Abstract][Full Text] [Related]
5. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
[TBL] [Abstract][Full Text] [Related]
6. APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy.
Bruggeman LA; Wu Z; Luo L; Madhavan S; Drawz PE; Thomas DB; Barisoni L; O'Toole JF; Sedor JR
PLoS One; 2019; 14(10):e0224408. PubMed ID: 31661509
[TBL] [Abstract][Full Text] [Related]
7. APOL1 localization in normal kidney and nondiabetic kidney disease.
Madhavan SM; O'Toole JF; Konieczkowski M; Ganesan S; Bruggeman LA; Sedor JR
J Am Soc Nephrol; 2011 Nov; 22(11):2119-28. PubMed ID: 21997392
[TBL] [Abstract][Full Text] [Related]
8. From man to fish: What can Zebrafish tell us about ApoL1 nephropathy?
Olabisi O; Al-Romaih K; Henderson J; Tomar R; Drummond I; MacRae C; Pollak M
Clin Nephrol; 2016 Supplement 1; 86 (2016)(13):114-118. PubMed ID: 27509583
[TBL] [Abstract][Full Text] [Related]
9. Disrupted apolipoprotein L1-miR193a axis dedifferentiates podocytes through autophagy blockade in an APOL1 risk milieu.
Kumar V; Ayasolla K; Jha A; Mishra A; Vashistha H; Lan X; Qayyum M; Chinnapaka S; Purohit R; Mikulak J; Saleem MA; Malhotra A; Skorecki K; Singhal PC
Am J Physiol Cell Physiol; 2019 Aug; 317(2):C209-C225. PubMed ID: 31116585
[TBL] [Abstract][Full Text] [Related]
10. Effect of
Haque S; Patil G; Mishra A; Lan X; Popik W; Malhotra A; Skorecki K; Singhal PC
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28385815
[TBL] [Abstract][Full Text] [Related]
11. Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines.
Ma L; Shelness GS; Snipes JA; Murea M; Antinozzi PA; Cheng D; Saleem MA; Satchell SC; Banas B; Mathieson PW; Kretzler M; Hemal AK; Rudel LL; Petrovic S; Weckerle A; Pollak MR; Ross MD; Parks JS; Freedman BI
J Am Soc Nephrol; 2015 Feb; 26(2):339-48. PubMed ID: 25012173
[TBL] [Abstract][Full Text] [Related]
12. APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.
Bruggeman LA; Wu Z; Luo L; Madhavan SM; Konieczkowski M; Drawz PE; Thomas DB; Barisoni L; Sedor JR; O'Toole JF
J Am Soc Nephrol; 2016 Dec; 27(12):3600-3610. PubMed ID: 27026370
[TBL] [Abstract][Full Text] [Related]
13. Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population.
Behar DM; Kedem E; Rosset S; Haileselassie Y; Tzur S; Kra-Oz Z; Wasser WG; Shenhar Y; Shahar E; Hassoun G; Maor C; Wolday D; Pollack S; Skorecki K
Am J Nephrol; 2011; 34(5):452-9. PubMed ID: 21968148
[TBL] [Abstract][Full Text] [Related]
14. APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress.
Wen H; Kumar V; Lan X; Shoshtari SSM; Eng JM; Zhou X; Wang F; Wang H; Skorecki K; Xing G; Wu G; Luo H; Malhotra A; Singhal PC
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29967295
[TBL] [Abstract][Full Text] [Related]
15. Protein domains of APOL1 and its risk variants.
Lan X; Wen H; Lederman R; Malhotra A; Mikulak J; Popik W; Skorecki K; Singhal PC
Exp Mol Pathol; 2015 Aug; 99(1):139-44. PubMed ID: 26091559
[TBL] [Abstract][Full Text] [Related]
16. APOL1-Mediated Cell Injury Involves Disruption of Conserved Trafficking Processes.
Kruzel-Davila E; Shemer R; Ofir A; Bavli-Kertselli I; Darlyuk-Saadon I; Oren-Giladi P; Wasser WG; Magen D; Zaknoun E; Schuldiner M; Salzberg A; Kornitzer D; Marelja Z; Simons M; Skorecki K
J Am Soc Nephrol; 2017 Apr; 28(4):1117-1130. PubMed ID: 27864431
[No Abstract] [Full Text] [Related]
17. Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype.
Ekulu PM; Adebayo OC; Decuypere JP; Bellucci L; Elmonem MA; Nkoy AB; Mekahli D; Bussolati B; van den Heuvel LP; Arcolino FO; Levtchenko EN
Cells; 2021 Jul; 10(8):. PubMed ID: 34440683
[TBL] [Abstract][Full Text] [Related]
18. APOL1 toxin, innate immunity, and kidney injury.
Limou S; Dummer PD; Nelson GW; Kopp JB; Winkler CA
Kidney Int; 2015 Jul; 88(1):28-34. PubMed ID: 25853332
[TBL] [Abstract][Full Text] [Related]
19. Alterations in plasma membrane ion channel structures stimulate NLRP3 inflammasome activation in APOL1 risk milieu.
Jha A; Kumar V; Haque S; Ayasolla K; Saha S; Lan X; Malhotra A; Saleem MA; Skorecki K; Singhal PC
FEBS J; 2020 May; 287(10):2000-2022. PubMed ID: 31714001
[TBL] [Abstract][Full Text] [Related]
20. APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death.
Fu Y; Zhu JY; Richman A; Zhang Y; Xie X; Das JR; Li J; Ray PE; Han Z
J Am Soc Nephrol; 2017 Apr; 28(4):1106-1116. PubMed ID: 27864430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
